Penumbra, Inc. stock performance trend indicates that the stock price has rallied 28.43% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 8.5% . Looking at the past 52 week period, the stock price is up at 75.2% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Penumbra, Inc. has a positive value of 31.28 compared to overall market.Penumbra, Inc. is having a Relative Strength Index of 59.64 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Penumbra, Inc. (NYSE:PEN) has climbed 2.74% in the past week and advanced 4.7% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 2.5% and the outperformance has advanced to 3.51% for the last 4 weeks period.
For the current week, the company shares have a recommendation consensus of Buy. Penumbra, Inc. (NYSE:PEN) : On Friday heightened volatility was witnessed in Penumbra, Inc. (NYSE:PEN) which led to swings in the share price. The stock opened for trading at $79.7 and hit $84.8 on the upside , eventually ending the session at $82.45, with a gain of 6.32% or 4.9 points. The heightened volatility saw the trading volume jump to 1,925,729 shares. The 52-week high of the share price is $84.8 and the company has a market cap of $2,634 million. The 52-week low of the share price is at $43.68 .
Company has reported several Insider transactions to the SEC, on Mar 3, 2017, Robert D. Evans (EVP, Gen. Counsel & Secretary) sold 5,000 shares at 80.03 per share price.On Feb 14, 2017, Daniel Donen Davis (President, North America) sold 2,200 shares at 71.72 per share price.On Feb 14, 2017, Arani Bose (Chief Innovator) sold 7,700 shares at 72.67 per share price.
Penumbra Inc Last issued its quarterly earnings results on Feb 28, 2017. The company reported $-0.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $-0.09. The company had revenue of $73.10 million for the quarter, compared to analysts expectations of $67.54 million. The companys revenue was up 34.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS.
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The companys portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.